07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Axiogenesis AG, Sigma-Aldrich sales and marketing update

Sigma-Aldrich's Sigma Life Science biological products and services research business will market Axiogenesis' mouse induced pluripotent stem (iPS) cell-derived cardiomyocytes and smooth muscle cells. The companies said the iPS cell-derived primary cells enable long-term studies...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Company News

Axiogenesis AG, Kyoto University deal

Axiogenesis received a non-exclusive, worldwide license to an induced pluripotent stem (iPS) cell patent portfolio from the university's technology transfer arm, iPS Academia Japan Inc. Further terms were not disclosed. Axiogenesis AG , Cologne, Germany...